Improving BPH symptoms and sexual dysfunctions with a saw palmetto preparation? Results from a pilot trial

被引:13
作者
Suter, Andreas [1 ]
Saller, Reinhard [2 ]
Riedi, Eugen
Heinrich, Michael [3 ]
机构
[1] A Vogel Bioforce AG, Dept Med, Roggwil, Switzerland
[2] Univ Zurich Hosp, Inst Nat Med, CH-8091 Zurich, Switzerland
[3] Univ London, Sch Pharm, Univ Coll London, London WC1N 1AX, England
关键词
benign prostatic hyperplasia; sexual dysfunctions; clinical trial; saw palmetto; Serenoa repens; BENIGN PROSTATIC HYPERPLASIA; LOWER URINARY-TRACT; QUALITY-OF-LIFE; RECEPTOR-BINDING CHARACTERISTICS; SERENOA-REPENS EXTRACT; LONG-TERM EFFICACY; ERECTILE DYSFUNCTION; SILDENAFIL CITRATE; DOUBLE-BLIND; ALFUZOSIN;
D O I
10.1002/ptr.4696
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
In elderly men, benign prostatic hyperplasia (BPH) is a major risk factor for sexual dysfunctions (SDys). Additionally, the standard treatments for BPH symptoms, alpha blockers and 5-alpha-reductase inhibitors, cause SDys themselves. Preparations from saw palmetto berries are an efficacious and well-tolerated symptomatic treatment for mild to moderate BPH and have traditionally been used to treat SDys. We conducted an open multicentric clinical pilot trial to investigate whether the saw palmetto berry preparation Prostasan (R) influenced BPH symptoms and SDys. Eighty-two patients participated in the 8-week trial, taking one capsule of 320mg saw palmetto extract daily. At the end of the treatment, the International Prostate Symptom Score was reduced from 14.4 +/- 4.7 to 6.9 +/- 5.2 (p<0.0001); SDys measured with the brief Sexual Function Inventory improved from 22.4 +/- 7.2 to 31.4 +/- 9.2 (p<0.0001), and the Urolife BPH QoL-9 sex total improved from 137.3 +/- 47.9 to 195.0 +/- 56.3 (p<0.0001). Investigators' and patients' assessments confirmed the good efficacy, and treatment was very well tolerated and accepted by the patients. Correlation analyses confirmed the relationship between improved BPH symptoms and reduced SDys. This was the first trial with saw palmetto to show improvement in BPH symptoms and SDys as well. [Corrections made here after initial online publication.] Copyright (c) 2012 John Wiley & Sons, Ltd.
引用
收藏
页码:218 / 226
页数:9
相关论文
共 62 条
[1]   Pharmacologically Relevant Receptor Binding Characteristics and 5α-Reductase Inhibitory Activity of Free Fatty Acids Contained in Saw Palmetto Extract [J].
Abe, Masayuki ;
Ito, Yoshihiko ;
Yunzul, Luvsandori ;
Oki-Fujino, Tomomi ;
Yamada, Shizuo .
BIOLOGICAL & PHARMACEUTICAL BULLETIN, 2009, 32 (04) :646-650
[2]  
Bauer H W, 1999, MMW Fortschr Med, V141, P62
[3]  
Bennett BC, 1998, ECON BOT, V52, P381, DOI 10.1007/BF02862068
[4]   THE DEVELOPMENT OF HUMAN BENIGN PROSTATIC HYPERPLASIA WITH AGE [J].
BERRY, SJ ;
COFFEY, DS ;
WALSH, PC ;
EWING, LL .
JOURNAL OF UROLOGY, 1984, 132 (03) :474-479
[5]   Updated meta-analysis of clinical trials of Serenoa repens extract in the treatment of symptomatic benign prostatic hyperplasia [J].
Boyle, P ;
Robertson, C ;
Lowe, F ;
Roehrborn, C .
BJU INTERNATIONAL, 2004, 93 (06) :751-756
[6]   Lower urinary tract symptoms and erectile dysfunction: Co-morbidity or typical "aging male" symptoms? Results of the "Cologne male survey [J].
Braun, MH ;
Sommer, F ;
Haupt, G ;
Mathers, MJ ;
Reifenrath, B ;
Engelmann, UH .
EUROPEAN UROLOGY, 2003, 44 (05) :588-594
[7]  
BREU W, 1992, ARZNEIMITTELFORSCH, V42-1, P547
[8]   Medical therapy for benign prostatic hyperplasia: sexual dysfunction and impact on quality of life [J].
Carbone, DJ ;
Hodges, S .
INTERNATIONAL JOURNAL OF IMPOTENCE RESEARCH, 2003, 15 (04) :299-306
[9]  
Carraro JC, 1996, PROSTATE, V29, P231, DOI 10.1002/(SICI)1097-0045(199610)29:4<231::AID-PROS4>3.0.CO
[10]  
2-E